title: Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer.
abstract: BACKGROUND
  The chronomodulated infusion of 5-FU, FA and oxaliplatin allows a significant increase in dose intensity and antitumor efficacy in patients with metastatic colorectal cancer. Here we investigated if substitution of oxaliplatin with cisplatin produced a similar antitumor activity in previously untreated patients with advanced colorectal cancer.
  
  
  METHODS
  We enrolled 21 consecutively evaluated ambulatory patients with metastatic colorectal cancer. Each treatment cycle consisted of a 5-day course of continuous chronomodulated venous infusion of drugs. Daily doses were 600 mg/m2 5-FU, 150 mg/m2 FA (L-form), and 12 mg/m2 cisplatin. The cycles were repeated every 21 days.
  
  
  RESULTS
  All patients completed at least 3 cycles. Overall a total number of 105 cycles were administered. One partial response (lasting 3 months) and 13 stable disease (lasting from 3 to 12 months) were observed. The remaining 7 patients had progression of the disease. Hematologic and gastrointestinal toxicity was always < or = G2 in all cycles.
  
  
  CONCLUSIONS
  The results of this study discourage the substitution of cisplatin for the more active compound, oxaliplatin, in a chronomodulated schedule of infusion with 5-FU and FA in patients with metastatic colorectal cancer.
authors.affiliation: Department of Oncology and Neurosciences, University G. D'Annunzio, Chieti, Italy. natoli@unich.it
authors.forename: C
authors.initials: C
authors.lastname: Natoli
authors.forename: M T
authors.initials: MT
authors.lastname: Scognamiglio
authors.forename: M T
authors.initials: MT
authors.lastname: Martino
authors.forename: L
authors.initials: L
authors.lastname: Irtelli
authors.forename: M
authors.initials: M
authors.lastname: De Tursi
authors.forename: E
authors.initials: E
authors.lastname: Cianchetti
authors.forename: E
authors.initials: E
authors.lastname: Mascitelli
authors.forename: N
authors.initials: N
authors.lastname: Tinari
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002940:Circadian Rhythm; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil